Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Non-Current Liabilities (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Total Non-Current Liabilities data on record, last reported at $38.0 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities rose 11.63% year-over-year to $38.0 million; the TTM value through Sep 2025 reached $38.0 million, up 11.63%, while the annual FY2024 figure was $37.4 million, 25.97% up from the prior year.
  • Total Non-Current Liabilities reached $38.0 million in Q3 2025 per NWBO's latest filing, up from $32.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $38.0 million in Q3 2025 and bottomed at $10.1 million in Q3 2022.
  • Average Total Non-Current Liabilities over 5 years is $24.5 million, with a median of $22.3 million recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 392.71% in 2021, then tumbled 65.9% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $30.4 million in 2021, then crashed by 65.9% to $10.4 million in 2022, then surged by 186.81% to $29.7 million in 2023, then rose by 25.97% to $37.4 million in 2024, then rose by 1.38% to $38.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $38.0 million in Q3 2025, $32.3 million in Q2 2025, and $29.3 million in Q1 2025.